Compare IPST & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPST | ENVB |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.0M |
| IPO Year | N/A | 2000 |
| Metric | IPST | ENVB |
|---|---|---|
| Price | $5.29 | $2.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $164.00 | N/A |
| AVG Volume (30 Days) | 542.4K | ★ 8.3M |
| Earning Date | 04-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | $70.16 | N/A |
| Revenue Next Year | $60.33 | N/A |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.24 | $0.56 |
| 52 Week High | $15.08 | $13.25 |
| Indicator | IPST | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 64.68 | 46.41 |
| Support Level | $5.15 | $1.22 |
| Resistance Level | $6.71 | $4.48 |
| Average True Range (ATR) | 0.86 | 0.94 |
| MACD | 0.06 | -0.20 |
| Stochastic Oscillator | 74.57 | 5.57 |
IP Strategy Holdings Inc operate a diversified business centered on digital asset-based infrastructure and intellectual property (IP) management, supplemented by a legacy craft spirits operating segment. The Company provides public market investors with broad exposure to the around $80 trillion programmable intellectual property economy in a regulated equity format. Its treasury reserve of $IP tokens provides direct participation in the Story ecosystem, which enables on-chain registration, licensing, and monetization of intellectual property.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.